As {INVENTED NAME} contains pseudo-ephedrine it is also contraindicated in patients who are receiving monoamine oxidase (MAO) inhibitor therapy or during the 2 weeks following the stopping of such treatment, and in patients with: − narrow-angle glaucoma, − urinary retention, − cardiovascular diseases such as ischaemic heart disease, tachyarrhythmia and severe hypertension − hyperthyroidism − a history of haemorhagic stroke or with risk factors which could increase the risk of haemorhagic stroke, due to the alpha-mimetic activity of the vasoconstrictor, in combination with vasoconstrictors such as bromocriptine, pergolide, lisuride, cabergoline, ergotamine, dihydroergotamine or any other decongestant drug used as nasal decongestant, either by oral route or by nasal route (phenylpropanolamine, phenylephrine, ephedrine…).